The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry

  • Peter Bramlage, Roland E. Schmieder, Anselm K. Gitt, Peter Baumgart, Felix Mahfoud, Hartmut Buhck, Taoufik Ouarrak, Martina Ehmen, Sebastian A. Potthoff
  • Trials, December 2015, Springer Science + Business Media
  • DOI: 10.1186/s13063-015-1100-8

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Peter Bramlage